Ads
related to: how does sglt2 inhibitors work in the heart attack symptoms- FAQs
Your Heart Failure Questions.
Are Answered Here.
- Your Treatment Plan
What To Look Out For.
Begin Your Treatment.
- Benefits
Learn More About.
What It Can Do.
- Real Tips & Advice
Get Helpful Tips And Advice.
Sign Up For Patient Support.
- Doctor Discussion Guide
Discover Helpful Questions.
Bring To Your Next Appointment.
- Sign Up For Savings
Check Your Savings Eligibility.
Pay As Little As $10/Month.
- FAQs
Search results
Results From The WOW.Com Content Network
The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
SGLT2 inhibitors, also called gliflozins, [14] are used in the treatment of type 2 diabetes. SGLT2 is only found in kidney tubules and in conjunction with SGLT1 resorbs glucose into the blood from the forming urine. By inhibiting SGLT2, and not targeting SGLT1, glucose is excreted which in turn lowers blood glucose levels.
SGLT2 is a member of the sodium glucose cotransporter family, which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney. [6] SGLT2 is located in the early proximal tubule, and is responsible for reabsorption of 80-90% of the glucose filtered by the kidney glomerulus. [7]
SGLT2 inhibitors, including canagliflozin, reduce the likelihood of hospitalization for congestive heart failure or progression of renal disease in persons with diabetes mellitus type 2 and reduce the likelihood of stroke and heart attack in persons with diabetes mellitus type 2 who have known atherosclerotic vascular disease.
The analysis showed that over a follow-up period of an average of 2.06 years for people on SGLT2 inhibitors, and 3.70 years for people on different antidiabetes drugs, there was a reduction in the ...
Ad
related to: how does sglt2 inhibitors work in the heart attack symptoms